Παρασκευή 13 Απριλίου 2018

Resistance to Antibody-Drug Conȷugates

Antibody–drug conjugates (ADC) are multicomponent molecules constituted by an antibody covalently linked to a potent cytotoxic agent. ADCs combine high target specificity provided by the antibody together with strong antitumoral properties provided by the attached cytotoxic agent. At present, four ADCs have been approved and over 60 are being explored in clinical trials. Despite their effectiveness, resistance to these drugs unfortunately occurs. Efforts to understand the bases underlying such resistance are being carried out with the final purpose of counteracting them. In this review, we report described mechanisms of resistance to ADCs used in the clinic along with other potential ones that may contribute to resistance acquisition. We also discuss strategies to overcome resistance to ADCs. Cancer Res; 1–7. ©2018 AACR.

from Cancer via ola Kala on Inoreader https://ift.tt/2JJ4F5v
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου